Soluble endoglin (sENG) is an important biomarker of several cardiometabolic and vascular disorders. The accurate measurement of biomarkers that are simultaneously targeted by therapeutic monoclonal antibodies (mAbs) in preclinical models is a significant challenge. Traditional enzyme-linked immunosorbent assays (ELISAs) often fail due to epitope blocking, while advanced techniques like mass spectrometry are more expensive and require specialized expertise. To address these limitations, we developed a cost-effective, specific Western blot-based method for evaluating sENG in mouse plasma in a metabolic dysfunction-associated steatohepatitis (MASH) rescue model. Thus, from a methodological perspective, we significantly modified and extended the sENG detection method introduced in our previous work, focusing on developing a cost-effective approach for semi-quantitative analysis. For these purposes, we used a mouse MASH model treated with the anti-endoglin (ENG) mAb M1043. Plasma samples were concentrated, and proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and probed with an anti-ENG antibody. We verified the method using human hepatic sinusoidal endothelial cells (HHSECs) culture media treated with the therapeutic human anti-ENG monoclonal antibody, TRC105. This Western blot-based approach avoids interference from therapeutic mAbs, delivering reliable and reproducible results. This method overcomes the limitations of ELISAs and mass spectrometer, providing a practical solution for semi-quantitative analysis of biomarkers in both preclinical and clinical research. Its versatility makes it applicable to various soluble protein biomarkers across diseases. As therapeutic mAbs become more widely used, this simple, cost-effective method facilitates mechanistic insights and accelerates targeted therapy development in research.

Department of Biological and Medical Sciences Faculty of Pharmacy in Hradec Kralove Charles University Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

Department of Clinical Immunology and Allergology Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Zobrazit více v PubMed

Vicen, M. et al. Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. PubMed PMC

Ikemoto, T. et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. PubMed

Zhang, J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. PubMed

Margioula-Siarkou, G. et al. Soluble endoglin concentration in maternal blood as a diagnostic biomarker of preeclampsia: A systematic review and meta-analysis. PubMed

Eissazadeh, S. et al. Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo. PubMed

Igreja Sá, I. C. et al. Soluble endoglin as a potential biomarker of nonalcoholic steatohepatitis (NASH) development, participating in aggravation of NASH-related changes in mouse liver. PubMed PMC

Eissazadeh, S. et al. Anti-Endoglin monoclonal antibody prevents the progression of liver sinusoidal endothelial inflammation and fibrosis in MASH. PubMed

Leanos-Miranda, A. et al. Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. PubMed

Schoonderwoerd, M. J. et al. Targeting endoglin-expressing regulatory T cells in the tumor microenvironment enhances the effect of PD1 checkpoint inhibitor immunotherapy. PubMed

González-Muñoz, T. et al. Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis. PubMed

Smirnov, I. V. et al. New highly sensitive sandwich ELISA system for soluble endoglin quantification in different biological fluids. PubMed

Juraskova, B. et al. Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer’s disease patients. PubMed

Anık, A., Çelik, E., Çevik, Ö., Ünüvar, T. & Anık, A. The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus. PubMed

Levine, R. J. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. PubMed

Chen, Y. et al. Soluble endoglin modulates aberrant cerebral vascular remodeling. PubMed PMC

Ruiz-Remolina, L. et al. Circulating soluble endoglin modifies the inflammatory response in mice. PubMed PMC

Puspitasari, M. K., Anwar, A. D. & Wirakusumah, F. F. Soluble endoglin serum level is higher in preeclampsia compared to molar and normal pregnancy.

Grebenchtchikov, N. et al. Quantification of patient-specific assay interference in different formats of enzyme-linked immunoassays for therapeutic monoclonal antibodies. PubMed

Tate, J. & Ward, G. Interferences in immunoassay. PubMed PMC

Ostrov, B. E. & Amsterdam, D. The interference of monoclonal antibodies with laboratory diagnosis: Clinical and diagnostic implications. PubMed

Liu, Y. et al. Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. PubMed PMC

Ma, Y. et al. Liquid chromatography-tandem mass spectrometry in clinical laboratory protein measurement. PubMed

Greenwood, C. et al. Proximity assays for sensitive quantification of proteins. PubMed PMC

Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. PubMed PMC

Liu, Y. et al. Western blotting via proximity ligation for high performance protein analysis. PubMed PMC

Kinhikar, A. et al. Recommendations for development and validation of a Fit-For-purpose biomarker assays using western blotting; an-AAPS sponsored initiative to harmonize industry practices. PubMed

Graham, M. L. & Prescott, M. J. The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease. PubMed PMC

Venkatesha, S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. PubMed

Hawinkels, L. J. et al. Matrix metalloproteinase-14 (MT1-MMP)–mediated endoglin shedding inhibits tumor angiogenesis. PubMed

El Hamaoui, D. et al. Thrombin cleaves membrane-bound endoglin potentially contributing to the heterogeneity of circulating endoglin in preeclampsia. PubMed PMC

Sumner, G. et al. Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kit. PubMed

Zheng, R. et al. A high-sensitivity low-nanoflow LC-MS configuration for high-throughput sample-limited proteomics. PubMed PMC

Reinders, J., Lewandrowski, U., Moebius, J., Wagner, Y. & Sickmann, A. Challenges in mass spectrometry-based proteomics. PubMed

Gowda, G. N. & Djukovic, D. Overview of mass spectrometry-based metabolomics: Opportunities and challenges. PubMed PMC

Bhawal, R., Oberg, A. L., Zhang, S. & Kohli, M. Challenges and opportunities in clinical applications of blood-based proteomics in cancer. PubMed PMC

Owen, C., Fader, K. A. & Hassanein, M. Western blotting: Evolution of an old analytical method to a new quantitative tool for biomarker measurements. PubMed

Mahmood, T. & Yang, P.-C. Western blot: Technique, theory, and trouble shooting. PubMed PMC

Liu, Z.-Q., Mahmood, T. & Yang, P.-C. Western blot: Technique, theory and trouble shooting. PubMed PMC

Gassmann, M., Grenacher, B., Rohde, B. & Vogel, J. Quantifying Western blots: Pitfalls of densitometry. PubMed

Ghosh, R., Gilda, J. E. & Gomes, A. V. The necessity of and strategies for improving confidence in the accuracy of western blots. PubMed PMC

Sormunen, A. et al. Comparison of automated and traditional Western blotting methods. PubMed PMC

Anderson, G. J., Cipolla, M. C. & Kennedy, R. T. Western blotting using capillary electrophoresis. PubMed PMC

Rustandi, R. R., Hamm, M., Lancaster, C. & Loughney, J. W. Applications of an automated and quantitative CE-based size and charge western blot for therapeutic proteins and vaccines. PubMed